Rallybio (RLYB) Competitors $0.26 -0.01 (-3.07%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.27 +0.01 (+2.71%) As of 04/15/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLYB vs. CRBU, CRDL, HLVX, MGNX, RENB, ALTS, ANL, VOR, VTGN, and IFRXShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Caribou Biosciences (CRBU), Cardiol Therapeutics (CRDL), HilleVax (HLVX), MacroGenics (MGNX), Renovaro (RENB), Janone (ALTS), Adlai Nortye (ANL), Vor Biopharma (VOR), Vistagen Therapeutics (VTGN), and InflaRx (IFRX). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. Caribou Biosciences Cardiol Therapeutics HilleVax MacroGenics Renovaro Janone Adlai Nortye Vor Biopharma Vistagen Therapeutics InflaRx Rallybio (NASDAQ:RLYB) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking. Does the MarketBeat Community prefer RLYB or CRBU? Rallybio received 18 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 73.33% of users gave Rallybio an outperform vote while only 61.90% of users gave Caribou Biosciences an outperform vote. CompanyUnderperformOutperformRallybioOutperform Votes4473.33% Underperform Votes1626.67% Caribou BiosciencesOutperform Votes2661.90% Underperform Votes1638.10% Is RLYB or CRBU more profitable? Rallybio has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,290.81%. Caribou Biosciences' return on equity of -45.46% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets RallybioN/A -77.39% -69.33% Caribou Biosciences -1,290.81%-45.46%-38.07% Which has more risk & volatility, RLYB or CRBU? Rallybio has a beta of -1.35, indicating that its stock price is 235% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Do insiders & institutionals believe in RLYB or CRBU? 90.3% of Rallybio shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 7.4% of Rallybio shares are owned by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor RLYB or CRBU? In the previous week, Rallybio had 18 more articles in the media than Caribou Biosciences. MarketBeat recorded 19 mentions for Rallybio and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.47 beat Rallybio's score of 0.04 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Rallybio Neutral Caribou Biosciences Neutral Which has better earnings & valuation, RLYB or CRBU? Rallybio has higher earnings, but lower revenue than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybio$636K17.14-$74.56M-$1.35-0.19Caribou Biosciences$9.99M7.25-$102.07M-$1.65-0.47 Do analysts prefer RLYB or CRBU? Rallybio currently has a consensus price target of $9.33, suggesting a potential upside of 3,463.70%. Caribou Biosciences has a consensus price target of $10.33, suggesting a potential upside of 1,226.32%. Given Rallybio's higher possible upside, equities research analysts plainly believe Rallybio is more favorable than Caribou Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryRallybio beats Caribou Biosciences on 10 of the 18 factors compared between the two stocks. Remove Ads Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.90M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.166.7921.7317.81Price / Sales17.14225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book0.095.866.464.00Net Income-$74.56M$141.86M$3.20B$247.23M7 Day Performance4.76%4.50%2.85%1.45%1 Month Performance-58.56%-12.65%-8.55%-6.24%1 Year Performance-85.45%-11.06%10.46%0.60% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio2.399 of 5 stars$0.26-3.1%$9.33+3,463.7%-85.7%$10.90M$636,000.00-0.1640Analyst DowngradeNews CoverageGap DownCRBUCaribou Biosciences2.2422 of 5 stars$0.76-1.3%$10.33+1,264.3%-80.9%$70.44M$9.99M-0.46100CRDLCardiol Therapeutics1.8048 of 5 stars$0.85+4.9%$8.40+888.2%-40.8%$70.22MN/A-2.1820News CoverageGap DownHLVXHilleVax2.3708 of 5 stars$1.40-1.4%$3.00+114.3%-88.1%$70.20MN/A-0.4520Positive NewsMGNXMacroGenics3.7213 of 5 stars$1.10+3.8%$7.38+570.5%-92.6%$69.40M$148.34M-0.70430Positive NewsRENBRenovaro0.6532 of 5 stars$0.43+10.5%N/A-84.8%$68.88MN/A-0.4720ALTSJanoneN/A$4.26-8.0%N/AN/A$68.50M$12.53M0.00170Short Interest ↑ANLAdlai Nortye1.5391 of 5 stars$1.86-7.7%$9.00+385.2%-81.3%$68.45M$5M0.00127Upcoming EarningsShort Interest ↑VORVor Biopharma1.798 of 5 stars$0.54-4.1%$8.86+1,529.0%-61.1%$67.88MN/A-0.33140VTGNVistagen Therapeutics1.7464 of 5 stars$2.17-7.7%N/A-53.3%$67.83M$698,000.00-1.4740IFRXInflaRx2.15 of 5 stars$1.01flat$9.00+791.1%-20.9%$67.80M$165,789.00-0.9460Short Interest ↑Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Caribou Biosciences Alternatives Cardiol Therapeutics Alternatives HilleVax Alternatives MacroGenics Alternatives Renovaro Alternatives Janone Alternatives Adlai Nortye Alternatives Vor Biopharma Alternatives Vistagen Therapeutics Alternatives InflaRx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLYB) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLYB Stock Free RLYB Stock Alerts